Guardant Health and Zephyr AI have partnered to advance the discovery of novel cancer biomarkers, as more precise tumour ...

The United States Prostate Cancer Biomarkers Market is projected to grow from $1.48 billion in 2024 to $3.54 billion by 2033, ...

Adelaide researchers have identified a promising new biomarker and treatment target for ovarian cancer that could markedly ...

Oncology-focused biotech company Guardant Health is partnering with AI drug development company Zephyr AI to combine AI and ...

Cizzle Bio Inc. founder and CEO Bill Behnke moderated a high-profile panel at the 2025 Association for Value-Based Cancer ...

Biomarkers are pivotal for confirming diagnoses, predicting disease progression, and tailoring therapeutic modalities. Recent ...

The researchers argue that the integration of explainable AI into clinical decision-making pipelines could reshape cancer ...

Circulating tumor DNA (ctDNA) is a promising biomarker for monitoring treatment response and progression-free survival in ...

A recent publication in JACC: Advances shows a previously unrecognized link between cardiac disease and cancer. The research focused on cardiac biomarkers, which are biological molecules that can ...

Early detection and prevention of cancer can save lives, but current tools often fall short because of suboptimal accuracy and limited accessibility. The Fred Hutch Cancer Center aims to change that ...

Please provide your email address to receive an email when new articles are posted on . Elevated levels of cardiac biomarkers were indicative of future cancer risk. The association between biomarkers ...